Literature DB >> 12799229

Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states.

Melissa M Brown1, Gary C Brown, Sanjay Sharma, Brandon Busbee.   

Abstract

PURPOSE: To assess the visual utility values of patients with ocular disease and to compare these values with those of patients with systemic health states
DESIGN: Cross-sectional utility value assessment.
METHODS: Consecutive patients with ophthalmic diseases were interviewed in a one-on-one fashion using a standardized time tradeoff utility value assessment form. These values were compared with utility values for systemic health states present in the literature. INTERVENTION: None. MAIN OUTCOME MEASURE: Time tradeoff utility value on a scale ranging from 1.0 (perfect visual health) to 0.0 (death). The ophthalmic patient groups were stratified into 4 visual groups dependent on the visual acuity in the better-seeing eye. The groups were as follows: group 1, 20/20 to 20/25; group 2, 20/30 to 20/50; group 3, 20/60 to 20/100; group 4, 20/200 to no light perception.
RESULTS: A total of 500 subjects were enrolled in the study. The mean utility values for the visually stratified groups were: group 1, 0.88; group 2, 0.81; group 3, 0.72; group 4, 0.61. Comparable respective systemic health state utility values for each of the ophthalmic groups were: diabetes mellitus, status after kidney transplantation, moderate stroke, and moderately severe stroke.
CONCLUSIONS: Visual loss is associated with a substantial and measurable diminution in quality of life. This diminution in quality of life can be directly compared with that induced by systemic health states.

Entities:  

Mesh:

Year:  2003        PMID: 12799229     DOI: 10.1016/S0161-6420(03)00254-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  35 in total

1.  How much blue light should an IOL transmit?

Authors:  M A Mainster; J R Sparrow
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

2.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

Review 3.  Value-based medicine and ophthalmology: an appraisal of cost-utility analyses.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Heidi Brown; Lindsay Smithen; David B Leeser; George Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 4.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

5.  The burden of age-related macular degeneration: a value-based medicine analysis.

Authors:  Gary C Brown; Melissa M Brown; Sanjay Sharma; Joshua D Stein; Zachary Roth; Joseph Campanella; George R Beauchamp
Journal:  Trans Am Ophthalmol Soc       Date:  2005

6.  The impact of persistent visually disabling vitreous floaters on health status utility values.

Authors:  Haidong Zou; Haiyun Liu; Xun Xu; Xi Zhang
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

Review 7.  How the diabetic eye loses vision.

Authors:  Jaime A Davidson; Thomas A Ciulla; Janet B McGill; Keri A Kles; Pamela W Anderson
Journal:  Endocrine       Date:  2007-09-27       Impact factor: 3.633

8.  Variation in treatment preferences and care goals among older patients with diabetes and their physicians.

Authors:  Marshall H Chin; Melinda L Drum; Lei Jin; Morgan E Shook; Elbert S Huang; David O Meltzer
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

9.  Intrastromal corneal ring implants for corneal thinning disorders: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-04-01

10.  Collagen cross-linking using riboflavin and ultraviolet-a for corneal thinning disorders: an evidence-based analysis.

Authors:  G Pron; L Ieraci; K Kaulback
Journal:  Ont Health Technol Assess Ser       Date:  2011-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.